Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Rhythm Society Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Neurostimulation for heart failure: Medtronic will launch a study to evaluate spinal cord stimulation for the treatment of heart failure in the next few weeks, cardiologist Douglas Zipes announced at HRS. Zipes and other speakers discussed the emerging role of neurostimulation devices, such as Medtronic's PrimeADVANCED neurostimulator and BioControl Medica's CardioFit vagus nerve stimulation device, to treat heart failure and cardiac arrhythmias. Neither devices are approved in the U.S. "There is a huge market for improving ventricular function over the present therapies," such as defibrillation, Zipes, of Krannert Institute of Cardiology in Indianapolis, said. "This is a major advance." Zipes will be lead investigator of Medtronic's DEFEAT-HF study
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel